Papers/PMID:20334471
Magnesium sulphate in the management of patients with aneurysmal subarachnoid haemorrhage: a meta-analysis of prospective controlled trials.
Brain injury2010The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
magnesium(2+) — increases withdrawal due to adverse events
Evidence strength: very limited.Finding“The withdrawal rate for adverse effects was higher in the magnesium-treatment arm compared to the placebo arm, RR 9.98 (95% CI 3.04-32.74).”
Quoted verbatim from Magnesium sulphate in the management of patients with aneurysmal subarachnoid haemorrhage: a meta-analysis of prospective controlled trials.. - Study
- meta-analysis
- Population
- Patients with aneurysmal subarachnoid haemorrhage in six pooled prospective controlled trials of intravenous magnesium
Effect 9.98 risk ratio, 95% CI 3.04 to 32.74
Magnesium sulphate in the management of patients with aneurysmal subarachnoid haemorrhage: a meta-analysis of prospective controlled trials.2010PMID:2033447110.3109/02699051003610516Permalink